Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

306
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
306
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

227
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
227
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
159
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

365
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
365
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

493
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
493
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

205
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
205

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.

bioRxiv : the preprint server for biology·2026
Same authorSame journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same author

IBD risk locus rs1077773 enhances aryl hydrocarbon receptor activity and modulates immune cell function in vitro.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Mucosally sourced complement factor B modulates the host response to colitis.

bioRxiv : the preprint server for biology·2026
Same author

Hidden Clues in the Epithelial Brush Border: A New Prognostic Marker for Pediatric Crohn's Disease.

Inflammatory bowel diseases·2025
Same author

Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines.

Cancer research communications·2025

相关实验视频

Updated: Jul 28, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K

在炎症性肠道疾病中的困难菌.

Tamara Alhobayb1, Matthew A Ciorba

  • 1Inflammatory Bowel Diseases Center and Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri, USA.

Current opinion in gastroenterology
|June 2, 2023
PubMed
概括

困难菌感染 (CDI) 在炎症性肠病 (IBD) 患者中很常见,可能会恶化发作并延长住院时间. 及时诊断和使用万科米辛或菲达克索米辛的治疗,以及预防策略,如便微生物群移植,至关重要.

科学领域:

  • 胃肠病学和传染病学
  • 微生物学和免疫学

背景情况:

  • 炎症性肠道疾病 (IBD),包括克罗恩氏病和性结肠炎,与具有症状的Clostridium difficile感染 (CDI) 的更高风险有关.
  • CDI可以模仿IBD爆发,使患者的管理复杂化,并导致发病率增加.

结论:

  • 在IBD患者诊断和治疗CDI时保持警至关重要.
  • 在IBD中CDI的可修改风险因素包括皮质类固醇使用,不必要的抗生素和活跃的肠道炎症.
  • 实施改进的感染控制,利用先进的IBD药物,并采用有效的CDI治疗,可以减少严重CDI及其IBD并发症的负担.

更多相关视频

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.6K
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.2K

相关实验视频

Last Updated: Jul 28, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.6K
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.2K